Page last updated: 2024-12-11
ostalloy
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
ostalloy: protective shield to reduce scatter dose to the testicle outside of radiation treatment field; composed of 50% bismuth, 26.7% lead, 13.3% tin & 10% cadmium; density 9.38g/cm(3) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6367222 |
| MeSH ID | M0111779 |
Synonyms (3)
| Synonym |
|---|
| ostalloy |
| bismuth lead tin cadmium ingot (wood's metal) |
| bismuth lead tin cadmium ingot (woods metal) |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Since 1980, five papers have addressed questions concerning potential metal toxicity, safe shop practices, measurement of airborne vapors and metal particulates, and the results of biological testing of personnel fabricating secondary field shaping blocks." | ( The safety of low melting point bismuth/lead alloys: a review. Glasgow, GP, 1991) | 0.28 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 24.83
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.83) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||